New reports show additional doses of Johnson & Johnson's (J&J) COVID-19 vaccine manufactured in Baltimore may be contaminated; legislation extends fentanyl's regulation as a Schedule 1 drug; COVID-19 cases and deaths increase in Texas.
Following reports of 15 million Johnson & Johnson (J&J) vaccine doses spoiled at a Baltimore plant earlier this month, federal regulators have now found more flaws at the facility, The New York Times reports. FDA officials say Emergent BioSolutions, the company manufacturing the vaccine, may have contaminated additional doses because it failed to fully investigate contamination and had faults in its disinfectant practices, handling of raw materials, and training of workers. No doses made at the plant have gone out to the public and all J&J doses distributed in the United States were manufactured overseas.
The US House of Representatives passed legislation to extend a provision set to expire that keeps fentanyl listed as a Schedule 1 drug, according to Roll Call. The deadly synthetic opioid has been responsible for a large proportion of drug overdoses in the United States in recent years. Its listing as a Schedule 1 drug, which would have expired May 6, means it has a high potential to be abused and does not have a medical use. In the 12 months preceding September 2020, at least 87,000 individuals died of drug overdoses. Under the revised version of the bill, fentanyl’s status would remain until October 22, 2021, granting lawmakers time to draft more comprehensive legislation.
COVID-19 deaths and cases continue to increase at an above-average pace in Texas, The Associated Press reports. The state recorded 4518 new cases and 82 COVID-19–related deaths compared with a rolling 7-day average of over 3200 cases and 55 deaths, according to researchers at Johns Hopkins University. Over the course of the pandemic, the state has reported just over 3 million cases and nearly 50,000 deaths, while currently, 36% of Texans have received at least 1 dose of a COVID-19 vaccine and 23% of the population is fully vaccinated.
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
Despite Record ACA Enrollment, Report Reveals Underinsured Americans Are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access to and affordability of health care.
Read More
Double Trouble: High-Deductible Plans Raise Maternity Care Costs Across 2 Calendar Years
June 27th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the June 2024 issue of The American Journal of Managed Care® about how annual high-deductible insurance plans increase maternity care costs when pregnancies cross 2 calendar years.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Support and Skepticism Emerge as Reactions to Robert F. Kennedy Jr’s HHS Nomination
November 15th 2024In the hours after President-elect Donald J. Trump tapped Robert F. Kennedy Jr to lead HHS, reactions came swiftly to the controversial pick who would have a large influence to shake up public health.
Read More